| 000 | 01893 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250518094214.0 | ||
| 264 | 0 | _c20200604 | |
| 008 | 202006s 0 0 fre d | ||
| 022 | _a1769-6917 | ||
| 024 | 7 |
_a10.1016/j.bulcan.2020.02.010 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAuditeau, Claire | |
| 245 | 0 | 0 |
_a[The role of direct oral anticoagulants in the management of cancer-associated thrombosis in 2020]. _h[electronic resource] |
| 260 |
_bBulletin du cancer _cMay 2020 |
||
| 300 |
_a574-585 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aATP Binding Cassette Transporter, Subfamily B _xmetabolism |
| 650 | 0 | 4 |
_aATP Binding Cassette Transporter, Subfamily G, Member 2 _xmetabolism |
| 650 | 0 | 4 |
_aAnticoagulants _xtherapeutic use |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xmetabolism |
| 650 | 0 | 4 |
_aCytochrome P-450 Enzyme System _xmetabolism |
| 650 | 0 | 4 |
_aDabigatran _xmetabolism |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 |
_aFactor Xa Inhibitors _xadverse effects |
| 650 | 0 | 4 |
_aHemorrhage _xchemically induced |
| 650 | 0 | 4 |
_aHeparin, Low-Molecular-Weight _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aNeoplasm Proteins _xmetabolism |
| 650 | 0 | 4 |
_aNeoplasms _xblood |
| 650 | 0 | 4 |
_aPyrazoles _xmetabolism |
| 650 | 0 | 4 |
_aPyridines _xmetabolism |
| 650 | 0 | 4 |
_aPyridones _xmetabolism |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 |
_aRivaroxaban _xmetabolism |
| 650 | 0 | 4 | _aSecondary Prevention |
| 650 | 0 | 4 |
_aThiazoles _xmetabolism |
| 650 | 0 | 4 |
_aThrombosis _xdrug therapy |
| 650 | 0 | 4 |
_aVenous Thromboembolism _xprevention & control |
| 700 | 1 | _aTalbot, Alexis | |
| 700 | 1 | _aBlandinières, Adeline | |
| 700 | 1 | _aSmadja, David M | |
| 700 | 1 | _aGendron, Nicolas | |
| 773 | 0 |
_tBulletin du cancer _gvol. 107 _gno. 5 _gp. 574-585 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.bulcan.2020.02.010 _zAvailable from publisher's website |
| 999 |
_c30820463 _d30820463 |
||